World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
78
Citations
30357
World Ranking
1721
National Ranking
846

Overview

Nicole A. Doria-Rose is affiliated with the National Institute of Allergy and Infectious Diseases in the United States. Their research primarily focuses on medicine and immunology and microbiology, with significant contributions in infectious diseases, virology, immunology, radiology and nuclear medicine, and molecular biology.

The scientist's work covers key topics including HIV research and treatment, monoclonal and polyclonal antibodies research, SARS-CoV-2 and COVID-19 research, immune cell function and interaction, animal virus infections studies, T-cell and B-cell immunology, and HIV/AIDS drug development and treatment.

Recent notable publications by Nicole A. Doria-Rose include:

  • "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report" (2020), New England Journal of Medicine
  • "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults" (2020), New England Journal of Medicine
  • "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness" (2020), Nature
  • "Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates" (2020), New England Journal of Medicine
  • "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination" (2020), New England Journal of Medicine

Collaborative work features frequent co-authors such as John R. Mascola, Peter D. Kwong, Sijy O'Dell, Bob C. Lin, and Mark K. Louder.

Publication venues where Nicole A. Doria-Rose has frequently appeared include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cell Reports
  • Nature Communications
  • SSRN Electronic Journal
  • New England Journal of Medicine

Best Publications

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts

  • Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

    Xueling Wu;Zhi Yong Yang;Yuxing Li;Carl Magnus Hogerkorp

  • SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.

    Kizzmekia S. Corbett;Darin K. Edwards;Sarah R. Leist;Olubukola M. Abiona

  • Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.

    Evan J. Anderson;Nadine G. Rouphael;Alicia T. Widge;Lisa A. Jackson

  • Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.

    Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica

  • Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

    Jinghe Huang;Gilad Ofek;Leo Laub;Mark K. Louder

  • Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing

    John R. Mascola;Gary Nabel;Barton F. Haynes;Xueling Wu

  • Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

    Nicole A. Doria-Rose;Chaim A. Schramm;Jason Gorman;Penny L. Moore

  • Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.

    Alicia T. Widge;Nadine G. Rouphael;Lisa A. Jackson;Evan J. Anderson

  • Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

    Nicole Doria-Rose;Mehul S. Suthar;Mat Makowski;Sarah O’Connell

  • Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.

    Pegu, Amarendra, O’Connell, Sarah E.;Stephen D. Schmidt;O’Dell, Sijy, Talana, Chloe A.

  • Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption

    Katharine J Bar;Michael C Sneller;Linda J Harrison;J Shawn Justement

  • Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface

    Jinghe Huang;Byong H. Kang;Marie Pancera;Jeong Hyun Lee

  • Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies

    Nicole A. Doria-Rose;Rachel M. Klein;Maura M. Manion;Sijy O'Dell

  • Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

    Davide Corti;John Misasi;Sabue Mulangu;Daphne A. Stanley

  • Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

    Jinghe Huang;Byong H. Kang;Elise Ishida;Tongqing Zhou

  • Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

    Young Do Kwon;Marie Pancera;Priyamvada Acharya;Ivelin S. Georgiev

  • Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables

    Nicole A. Doria-Rose;Rachel M. Klein;Marcus G. Daniels;Sijy O'Dell

  • Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody

    Rui Kong;Kai Xu;Tongqing Zhou;Priyamvada Acharya

  • Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16

    Marie Pancera;Syed Shahzad-Ul-Hussan;Nicole A. Doria-Rose;Jason S. McLellan

  • Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors

    Tongqing Zhou;Rebecca M. Lynch;Lei Chen;Priyamvada Acharya

Frequent Co-Authors

John R. Mascola
John R. Mascola ModeX Therapeutics
Peter D. Kwong
Peter D. Kwong Columbia University Medical Center
Mark K. Louder
Mark K. Louder National Institute of Allergy and Infectious Diseases
Sijy O'Dell
Sijy O'Dell National Institute of Allergy and Infectious Diseases
Lawrence Shapiro
Lawrence Shapiro Columbia University
Stephen D. Schmidt
Stephen D. Schmidt National Institutes of Health
Krisha McKee
Krisha McKee National Institute of Allergy and Infectious Diseases
Gwo-Yu Chuang
Gwo-Yu Chuang Moderna Therapeutics (United States)
Baoshan Zhang
Baoshan Zhang National Institute of Allergy and Infectious Diseases
Lynn Morris
Lynn Morris University of the Witwatersrand

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in studying Immunology in the USA, exploring related healthcare degrees can broaden career opportunities. Many students gravitate towards nursing, as it complements immunological knowledge with hands-on patient care. Starting with entry-level qualifications, the lpn programs easy to get into are a practical option for quickly entering the healthcare workforce.

Advancing further, nursing professionals often pursue specialized roles such as becoming nurse practitioners. The easy nurse practitioner programs to get into allow learners to efficiently progress their clinical expertise while managing patient care across a range of settings.

For those drawn to mental health, Psychiatric-Mental Health Nurse Practitioner programs are an excellent match. Programs like the online pmhnp programs with clinical placement offer strong practicum experiences, which are critical for licensure and competency in psychiatric nursing.

Cost can be a significant factor when choosing a program. Students benefit from researching affordable pmhnp programs that balance quality education with financial accessibility, making it easier to achieve their career goals without excessive debt.

Best Scientists Citing Nicole A. Doria-Rose

Trending Scientists